```
=> file caplus
FILE 'CAPLUS' ENTERED AT 16:18:44 ON 13 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 13 Oct 2010  VOL 153 ISS 16
FILE LAST UPDATED: 12 Oct 2010  (20101012/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Aug 2010

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d que
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3           18 SEA FILE=REGISTRY SSS FUL L1
L4            1 SEA FILE=CAPLUS L3


=> d l4 ibib abs hit

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2005:55204  CAPLUS
DOCUMENT NUMBER:          142:134581
TITLE:                    Preparation of malonamide derivatives useful as
                          raf-kinase inhibitors
INVENTOR(S):              Bruge, David; Buchstaller, Hans-Peter; Wiesner,
                          Matthias; Finsinger, Dirk; Baumgarth, Manfred;
                          Sirrenberg, Christian; Zenke, Frank; Amendt,
                          Christiane; Grell, Matthias
PATENT ASSIGNEE(S):       Merck Patent GmbH, Germany
SOURCE:                   PCT Int. Appl., 202 pp.
```

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005389	A2	20050120	WO 2004-EP6573	20040618
WO 2005005389	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004255566	A1	20050120	AU 2004-255566	20040618
AU 2004255566	B2	20100708		
CA 2531485	A1	20050120	CA 2004-2531485	20040618
EP 1641759	A2	20060405	EP 2004-740026	20040618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007508238	T	20070405	JP 2006-518009	20040618
US 20070213374	A1	20070913	US 2007-563830	20070125

PRIORITY APPLN. INFO.: EP 2003-14556 A 20030707
WO 2004-EP6573 W 20040618
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:134581
GI



I

AB Malonamide derivs. of formula A-D-B [wherein: D is (un)substituted bivalent malonamide moiety; A and B are independently selected from (hetero)aryl derivs.], useful as raf-kinase inhibitors (no biol. data), were prepared For instance, malonamide derivative I was obtained via amidation of 3-[(4-chloro-3-trifluoromethylphenyl)amino]-2-oxo-propionic acid by 4-(4-pyridinyloxy)phenylamine with a yield of 57%.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 827029-05-0P 827029-06-1P 827029-07-2P 827029-08-3P
827029-09-4P 827029-10-7P 827029-11-8P 827029-22-1P

827029-23-2P 827029-24-3P 827029-25-4P
827029-26-5P 827029-27-6P 827029-28-7P
827029-29-8P 827029-30-1P 827029-31-2P 827029-32-3P 827029-33-4P
827029-34-5P 827029-35-6P 827029-36-7P 827029-37-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of malonamide derivs. useful as raf-kinase inhibitors)

=>